# A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas

> **NCT05934838** · PHASE1 · RECRUITING · sponsor: **Weill Medical College of Cornell University** · enrollment: 15 (estimated)

## Conditions studied

- Follicular Lymphoma
- B-Cell Lymphoma
- Mantle Cell Lymphoma
- Diffuse Large B Cell Lymphoma

## Interventions

- **DRUG:** Tazemetostat Pill

## Key facts

- **NCT ID:** NCT05934838
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-04
- **Primary completion:** 2026-09
- **Final completion:** 2031-09
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2025-08-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05934838

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05934838, "A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT05934838. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*